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Abstract: Pulmonary hypertension (PH) is the hemodynamic manifestation of various 
pathological processes that result in elevated pulmonary artery pressures (PAP). The National 
Institutes of Health Registry defined pulmonary arterial hypertension as the mean PAP of more 
than 25 mm Hg with a pulmonary capillary wedge pressure or left atrial pressure equal to or 
less than 15 mm Hg. This definition remains the currently accepted definition of PH that is used 
to define PH related to multiple clinical conditions including chronic obstructive pulmonary 
disease (COPD). The estimated US prevalence of COPD by the National Health Survey in 
2002 in people aged 25 was 12.1 million. There is a lack of large population-based studies in 
COPD to document the correct prevalence of PH and outcome. The major cause of PH in COPD 
is hypoxemia leading to vascular remodeling. Echocardiogram is the initial screening tool of 
choice for PH. This simple noninvasive test can provide an estimate of right ventricular systolic 
and right atrial pressures. Right heart catheterization remains the gold standard to diagnose PH. 
It provides accurate measurement of mean PAP and pulmonary capillary wedge pressure. Oxygen 
therapy remains the cornerstone therapeutic for hypoxemia in COPD patients. Anecdotal reports 
suggest utility of  PDE5-inhibitors and prostacyclin to treat COPD-related PH. Large randomized 
clinical trials are needed before the use of these drugs can be recommended.
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Introduction
Pulmonary hypertension (PH) is the hemodynamic manifestation of various 
pathological processes that result in elevated pulmonary artery pressures (PAP).1,2 The 
current hemodynamic definition of PH is a mean PAP  25 mm Hg with a pulmonary 
capillary wedge pressure (PCWP), left atrial pressure or left ventricular end-diastolic 
pressure 15 mm Hg and pulmonary vascular resistance (PVR)  3 Wood units. 
These criteria define PH associated with multiple other disease processes including 
chronic obstructive pulmonary disease (COPD).3 In the current discussion, we will 
use this definition to define PH associated with COPD.
Epidemiology
COPD is a global disease caused by chronic exposure to airway irritants, most 
commonly tobacco smoke. Emerging literature suggests role of other irritants like 
biofuel smoke.4,5 The functional hallmark of the disease is airflow obstruction. COPD 
usually presents with respiratory symptoms and is confirmed by spirometry. The 
Global initiative for Chronic Obstructive Lung disease (GOLD) has defined COPD 
as post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital International Journal of COPD 2009:4 352
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capacity (FVC)  70.5 The disease is further classified into 
four stages based on calculated FEV1. The estimated US 
prevalence of COPD by the National Health Survey in 2002 
in people aged 25 was 12.1 million.6 The survey defined 
COPD as a positive response to the query “have you ever 
been told in the last 12 months by a doctor or health care pro-
fessional that you have chronic bronchitis or emphysema”. 
Two large population studies have reported the prevalence 
rates of COPD in multiple countries using GOLD criteria. 
Burden of obstructive disease initiative (BOLD) reported 
10.1% as prevalence of COPD stage II or higher.7 The Latin 
American project for the investigation of obstructive lung 
disease (PLATINO) reported 7.8% to 20% in various sites 
in South America.8
The exact prevalence of PH in patients with COPD is 
unclear.9 The diagnosis of PH in COPD patients is difficult. 
The published studies differ not only in their definition but 
also conditions under which PH was reported (rest, exercise, 
and exacerbation). Oswald-Mammosser and colleagues 
performed right heart catheterization (RHC) on 151 patients 
with COPD. The definition of PH was mean PAP  than 
20 mm Hg at rest and  than 30 mm Hg with exercise. 
21% of subjects had PH at rest and 66% with exercise.10 
PAP exhibited an inverse relationship with FEV1 and no 
relation to resting arterial oxygen saturation. Scharf and 
colleagues evaluated 120 patients recruited in the National 
Emphysema treatment trial (NETT).11 The authors stratified 
mean PAP into mild (20 mm Hg) moderate (21–35 mm Hg) 
and severe (35 mm Hg) categories. Moderate mean PAP 
was noted in 85.8% of patients and severe in 5% of the 
subjects.11 Patients included in this study had more severe 
airway obstruction (FEV1 27%) compared to prior study.10 
Regression analysis showed diffusion capacity and FEV1 
correlated with mean PAP. No relation between resting 
oxygen saturation and mean PAP was noted. Based on these 
studies an assumption can be made that worsening lung func-
tion is associated with increased incidence of PH. The burden 
of disease is probably high considering the high prevalence 
of COPD in various populations across the globe.5,7,8 The 
nature of relationship between airway obstruction (FEV1) 
and PH (defined by mean PAP) remains undefined.
Chaouat and colleagues evaluated 998 patients with 
COPD for presence of PH by RHC. Severe PH was defined 
as mean PAP  40 mm Hg.12 Twenty-seven patients had mean 
PAP  40 mm Hg and 11(1.1%) among these had COPD 
as the lone explanation. These patients were then compared 
to a control group of 30 COPD subjects. The control group 
had 16 patients with mean PAP  20 mm Hg. The study 
group showed mild to moderate airway obstruction, severe 
hypoxemia, hypocapnia, and very low diffusion capacity. This 
study shows the low prevalence of severe PH in COPD.
Thabut and colleagues performed RHC in 115 patients 
with COPD. The subjects were evaluated for lung volume 
reduction surgery (LVRS) and lung transplantation.13 PH 
(defined as mean PAP  25 mm Hg) was present in 50.2%. 
Moderate (mean PAP 35 to 45 mm Hg) in 9.8% and severe 
(mean PAP  45 mm Hg) in 3.7% of patients. Mean 
PAP was related to arterial partial pressure of oxygen and 
alveolar-arterial oxygen gradient in multivariate analysis. 
16 patients were noted with moderate airway limitation but 
strikingly elevated PAP.13 This study suggests a relatively 
high prevalence of PH in COPD patients, but severe PH is 
uncommon. The therapeutic implications of this finding are 
unclear currently.
The incidence of PH in COPD patients was evalu-
ated by Kessler and colleagues. The authors performed 
a longitudinal study on 131 patients with COPD by per-
forming serial RHC at baseline and than at follow-up 
(mean follow-up was 6.8 ± 2.9 years).14 All subjects had 
normal PAP at rest (20 mm Hg). They were divided 
into two groups based on presence or absence of elevated 
PAP with exercise (30 mm Hg) 25% of patients devel-
oped PH on follow up and was mild by hemodynamic 
criteria (mean PAP 26.8 ± 6.6 mm Hg). Subjects who 
exhibited elevated PAP with exercise were more likely to 
exhibit resting PAP elevation upon follow up. The rate of 
progression was +0.4 mm Hg per year. In a recent study by 
Moran-Mendoza, information on wood smoke-associated 
lung disease and PH was obtained prospectively. Subjects 
with 6 months of exposure to wood smoke were followed 
for five years. Postmortem pathological evaluation revealed 
no difference when compared to smokers in the presence 
of emphysema/bronchitis and pulmonary vascular changes. 
PH was defined based on a radiological index (hilar/thorasic 
index 38%) and was found to be more marked in females 
exposed to wood smoke.15
With the sparse literature available on incidence and 
prevalence of COPD-related PH, the following conclusions 
can be made. PH is usually mild in COPD and presence of 
severe PH (40 mm Hg) should lead to further investigation 
for alternative etiologies. Although the pulmonary pressure 
elevations in the majority COPD-related PH cases are mild to 
moderate in nature, there seems to be a small but significant 
group of patients in whom PH is severe despite relatively 
moderate airflow obstruction.13 This group may represent 
a separate population of patients with features similar to International Journal of COPD 2009:4 353
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patients with idiopathic PH. This may have significant 
prognostic and therapeutic implications.
Pathogenesis of pulmonary 
hypertension in COPD
Multiple animal and human experiments have tried to 
delineate the pathological processes involved in the develop-
ment of PH in COPD (Figure 1). The central stimulus to these 
processes remains chronic exposure of airways to noxious 
stimuli like cigarette and biofuel smoke. Exposure to these 
stimuli is a known inciting agent of airway inflammation 
leading to obstructive airway disease. Current evidence 
suggests role of airway irritants in addition to chronic airway 
inflammation in pulmonary vascular alterations. Discussed 
below are the various pathological processes involved in 
the pathogenesis of PH in COPD.
Hypoxia and hypercapnia
Hypoxia induced pulmonary vasoconstriction is a protective 
response to keep ventilation-perfusion ratio optimum by 
shunting blood away from the hypoxemic areas. The traditional 
hypoxic model of PH is based on the hypothesis that chronic 
hypoxia initiates vascular remodeling leading to permanent 
changes in pulmonary vasculature. Studies performed in vitro 
elucidated the mechanisms underlying hypoxia driven 
vascular changes.
Barbera and colleagues evaluated COPD patients 
undergoing lung resection.16 Subjects were stratified based 
on airflow obstruction and response to 100% oxygen. 
Histological evaluation of the pulmonary vasculature showed 
increased wall thickness secondary to intimal hyperplasia and 
decreased lumen size. These changes were more marked in 
the group with blunted response to oxygen. Animal models 
have demonstrated that PCO2 and pH has an additive effect 
in augmenting vasoconstrictor response of hypoxia. This 
hypothesis was tested in an anesthetized open chest dog 
model and the flow difference measured. There was 8% 
difference in flow when end-tidal PCO2 was elevated in 
the presence of hypoxia, compared to hypoxia alone.17 
Hypoxia may induce endothelial cells to release proliferate 
cytokine leading to cellular hypertrophy in the vessel wall 
and increase in extracellular matrix. These vascular changes 
Shear stress 
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Figure 1 Potential mechanisms leading to pulmonary hypertension in COPD.
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of COPD 2009:4 354
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contribute to vascular remodeling and putatively may have 
an effect on vascular dynamics leading to PH. These findings 
implicate a more complex mechanism than simple hypoxic 
vasoconstriction (which is the commonly accepted mecha-
nism for PH complicating lung disease) that has important 
therapeutic implications.
Polycythemia
Secondary polycythemia may be an adaptive response 
to hypoxemia. Polycythemia may lead to alteration of 
pulmonary vascular tone. In a study of 11 splenectomized 
dogs, McGrath increased the hematocrit from 43% to 65%. 
Polycythemia alone increased PVR by 112% (P  0.01) and 
hypoxia alone increased PVR by 141% (P  0.01). However, 
combined hypoxia and Polycythemia increased PVR by 
308% (P  0.005).18 Hasegawa and colleagues evaluated the 
role of polycythemia in mice. Study performed on transgenic 
mice with oxygen independent constitutive over expression 
of human erythropoietin. These mice become polycythemic 
at the age of 2 months with normal systemic hemodynamics 
compared to wild-type mice. Pulmonary artery pressure was 
elevated in vivo but not in vitro. This experiment provides 
proof to the concept that polycythemia can lead to elevated 
PAP.19 These studies suggest a role of polycythemia in 
the pathogenesis of PH. However, studies that evaluate 
this mechanism in COPD-related PH are needed.
Inflammation
Airway inflammation, induced by chronic cigarette smoking, 
may lead to pulmonary vascular changes. Cigarette smoke in 
rats induced proliferation of cells in pulmonary vasculature 
and in the airways.20 Chronic smokers with airway disease 
have changes in vascular structure compared to nonsmokers. 
Histological examination of pulmonary vasculature showed 
that smokers had twice as many muscularized arteries 
that were 0–300 µm in diameter compared to nonsmokers. 
In addition, there was increased fibrosis of arterial 
intima.21
In COPD patients who were smokers and with normal 
PAP, examination of post lobectomy/pneumonectomy lungs 
revealed increased number of leukocytes infiltrating the arte-
rial adventitia specifically CD8+ lymphocytes. Decreased 
endothelial dependent vascular relaxation in the pulmonary 
artery rings and increased vascular intimal thickness of the 
pulmonary muscular arteries noted.22 Monocrotaline has a 
marked predilection for pulmonary vascular endothelium 
and leads to the development of PH with marked inflam-
matory infiltration of the vessels.23 This model suggests the 
role of toxin-mediated pulmonary vascular inflammation in 
PH development.
Inflammatory cytokines such as interleukin-6 (IL-6), 
C-reactive protein, and tumor necrosis factor-α are markers 
of elevated PAP in COPD.24,25 Genetics may play a role and 
the LL phenotype of 5-HT gene is associated with higher 
PA pressures in hypoxemic COPD patients.26 IL-6 gene 
polymorphism is associated with higher serum levels of IL-6 
and higher PAP in COPD.25
Various models of PH induced by toxic substances, 
hypoxia, and sepsis have established the role of inflammation 
in PH. This supports the hypothesis that inflammation plays a 
role in inducing vascular changes in pulmonary circulation. 
Further elucidation of the precise mechanism by which 
inflammatory cells induce vascular remodeling and PH 
remains to be determined.
Shear stress
Viscous fluids moving in a cylindrical structure create shear 
stress on the vessel wall. If flow remains constant, shear 
stress is inversely related to the inner lumen of the vessel 
wall radius. As the luminal diameter decreases with vaso-
constriction, the shear stress in the vasculature increases. 
This constant stress on the vascular wall causes increased 
platelet degranulation, increase in inflammatory cytokine 
release, increase in expression of adhesion molecules, 
decrease in production of nitric oxide synthase and increased 
endothelin production.27,28 All these molecular changes can 
lead to alteration in pulmonary vasculature and increase 
PVR. Rabinovitch and colleagues altered pulmonary flow by 
banding single lungs in rats and exposed them to hypoxia.29 
Decreased pulmonary blood flow prevented vascular changes 
and muscularization of peripheral pulmonary arteries of the 
banded lungs in hypoxic rats when compared with the con-
tralateral lung with increased pulmonary blood flow. This 
experiment demonstrates that increased flow with hypoxia 
can augments smooth muscle content in pulmonary arteries. 
These studies suggest a role of shear stress in the presence 
of hypoxia in augmenting vascular remodeling.
endothelial dysfunction
Lungs of  COPD patients show impaired endothelium 
mediated vasodilatation when compared to non-COPD 
patients. In vitro relaxation of pulmonary artery rings 
obtained from patients with COPD reveal impaired relax-
ation to ADP suggesting that impaired endothelium-derived 
relaxation.22 Nitric oxide (NO) is recognized as an impor-
tant endothelium-derived vasodilator playing a major role International Journal of COPD 2009:4 355
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in maintaining vascular tone in normoxemic pulmonary 
vasculature.30 Smokers have decreased expression of endo-
thelial NO synthase in pulmonary endothelium.31 Increased 
shear may contribute to the increase in vascular tone in the 
presence of reduced NO production.28 Decreased NO pro-
duction due to endothelial dysfunction may have a role in 
PH in COPD. These pathological changes do have clinical 
significance in regards to therapy. Several agents exist cur-
rently which increase levels of NO and lead to pulmonary 
vasodilatation. 
Clinical features of pulmonary 
hypertension
History
Pulmonary hypertension clinically manifests as dyspnea. 
Patients may be asymptomatic especially in the early phase 
of the disease. As the disease progresses with continued 
elevation of PAP, the compensatory mechanisms get over-
whelmed. Symptoms may vary depending upon the severity 
of disease. Symptoms of cor pulmonale appear with patients 
experiencing fatigue, dyspnea, worsening exercise limitation, 
chest pains, abdominal distention, and pedal edema. When 
this phase continues unchecked, the right ventricle fails and 
cardiac output begins to fall. This phase may manifest with 
worsening symptoms progressing to presyncope or even 
syncope.32 As this process further progresses it leads to 
shock and death.
COPD can manifest clinically as dyspnea and exercise 
intolerance. Until symptoms of Cor pulmonale appear, it 
would be difficult to identify PH clinically in these patients. 
As shown by Chaouat and colleagues, PH in COPD is 
usually mild and it would be difficult to clinically delin-
eate from airway disease.12 During COPD exacerbations, 
some patients can develop pedal edema secondary to cor 
pulmonale with increased PAP and signs of right ventricular 
failure.33 Both hypoxia and hypercapnia affect the kidneys 
and encourage fluid retention. COPD patients during acute 
exacerbation may have elevated plasma renin activity and 
aldosterone levels that promote water and fluid retention.34 
The principle cause of fluid retention in COPD patients 
is probably right atrial stretching leading to sympathetic 
nervous system firing and downstream activation of the 
renin–angiotensin system. Hypercapnia is thought to 
exacerbate these effects. This hyperaldosteronism may be 
reversible by the treatment of acute exacerbation. Clinically 
it is difficult to identify PH in COPD patients in the absence 
of right heart failure.
The process of diagnosing PH in COPD patients should 
start with an evaluation geared to find clinical conditions 
commonly associated with elevated PAP (Table 1). Systemic 
hypertension is a common disease worldwide and associated 
with tobacco abuse. Left ventricular hypertrophy and associ-
ated diastolic dysfunction can lead to elevated pulmonary 
venous pressures and subsequent PH.35 Smoking is a known 
risk factor for coronary artery disease. Post myocardial left 
ventricular dysfunction is common cause of systolic heart 
failure and subsequent PH. Presence of obstructive sleep 
apnea (OSA) should be investigated as a contributing cause of 
PH in COPD. Symptoms suggestive of OSA include snoring, 
witnessed apneas and daytime somnolence.36 Collagen 
vascular diseases are associated with PH, and history and 
serologies should be undertaken to elicit autoimmune 
disorders. History of prior intravenous drug abuse, anorexiant 
use and use of natural health products should be sought. 
Other clinical conditions strongly associated with PH should 
be ruled out before attributing it to COPD.
Physical examination
Physical examination in PH would depend upon whether 
patient is in compensated or decompensated right heart 
failure. Physical examination finding in early compensated 
phase can be unclear. Accenuated P2 may be heard indicating 
Table 1 Conditions associated with pulmonary hypertension
Heart failure  
(Systolic/Diastolic)
Dyspnea, exercise intolerance, angina, 
prior myocardial infarctions, systemic 
hypertension, valvular heart disease
Current smoking Smoking cessation counseling, nicotine 
replacement therapy
Obstructive sleep apnea Snoring, excessive somnolence, 
witnessed apneic episodes
Autoimmune diseases History of skin changes, arthritis, 
gastrointestinal problems and renal disease
Chronic thromboembolic 
disease
Prior history of pulmonary embolism,  
deep vein thrombosis and genetic or 
acquired hypercoagulable conditions
Drug history Illicit drug abuse, prior anorexiant use 
and herbal products
Chronic liver disease History of jaundice, ascites, chronic viral 
hepatitis and alcohol abuse. Symptoms 
of portal hypertension including abdominal 
distention, and gastrointestinal bleed
HIv infection  Sexual behavior, intravenous drug abuse 
and needle sharing
Congenital diseases 
 
History of congenital heart disease and 
intracardiac shunts, family history of sickle 
cell diseaseInternational Journal of COPD 2009:4 356
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elevated PA pressures. Midsystolic murmur caused by 
turbulent flow across the pulmonary artery, left parasternal 
heave, right-sided S4 gallop and prominent jugular wave 
may be seen.32 As disease progresses, hepatojugular reflex 
and inspiratory augmented tricuspid murmur (Caravallo’s 
sign) may be evident. Signs of right heart failure include 
pulsatile liver, ascites, marked distention of jugular veins, 
and developing peripheral edema.2 Cardiovascular collapse 
due to severe cor pulmonale manifests as cold extremities 
and hypotension.
Many signs of classic PH would be altered in PH due 
to COPD. Loss of X descent with prominent V wave may 
suggest cor pulmonale in COPD patients. Hepatojugular 
reflex unmasks the murmur of tricuspid regurgitation and 
has 100% sensitivity and 66% specificity. Combined with 
Caravallo’s sign the specificity rises to 93%.37 Edema may 
be present in COPD patients with or without cor pulmonale 
during acute exacerbation.33 Auscultation would be difficult 
in these patients secondary to change in the position of heart. 
Point of maximal impulse may not palpable and advanced 
emphysematous patients may have small and vertical heart 
(drop heart).38
Diagnostic evaluation for pulmonary 
hypertension
PH in COPD patients is a clinical challenge to diagnose. 
In the absence of right heart failure, it is difficult to iden-
tify symptoms and signs attributable to elevated PAP. The 
authors experience of evaluating PH in COPD patients is 
serendipitous identification of elevated PAP on echocardio-
gram (ECHO). The other unusual scenario is patients with 
airway disease with overt right heart failure. We would like 
to describe the changes noted in noninvasive and invasive 
tests in COPD patients with PH.
electrocardiogram
Electrocardiogram (EKG) is a poor screening tool to diagnose 
PH. EKG findings suggestive of PH are right-axis deviation; 
tall R wave and small S wave with R/S ratio  1 in lead V1, 
qR complex in lead V1, rSR’ pattern in lead V1, large S 
wave and small R wave with R/S ratio  1 in lead V5 or V6; 
or S1, S2, S3 pattern. ST-T segment wave depression and 
inversion may be present in the right precordial leads. Right 
atrial enlargement manifests as a tall P wave (2.5 mm) in 
leads II, III, and aVF and frontal P-axis of 75°.32
Study performed in a cohort of patients with pulmo-
nary arterial hypertension (PAH) and PAH secondary to 
collagen vascular diseases documented abnormal EKG 
findings in 87% of these patients.39 No data exists regarding 
the predictive values and prognostic significance of EKG 
changes in COPD patients with PH. EKG may be useful in 
evaluating and excluding other conditions such as ischemic 
cardiomyopathy and left ventricular hypertrophy.
Radiological studies
Chest radiograph
Chest X-ray may reveal findings suggestive of PH. 
A radiological index obtained by measuring the horizontal 
distances from the midline to the first divisions of the right 
and left pulmonary arteries, and dividing the sum of these 
distances by the maximum transverse diameter of the thorax 
can predict PH. An abnormal index was suggestive of PH. 
However, this did not correlate with disease severity.40 This 
index may not be accurate in COPD patients in the presence 
of hyperinflation. Enlarged main and hilar pulmonary 
arterial shadows, with concomitant attenuation of periph-
eral pulmonary vascular markings (pruning) is suggestive 
of  PH. Right ventricular enlargement is seen on lateral films 
as impingement of the anteriorly situated right ventricular 
silhouette into the retrosternal clear space.2 The usefulness 
of these signs in patients with COPD is unknown.
echocardiogram
Echocardiogram (ECHO) is a commonly used screening 
tool for evaluating PH. It is a simple noninvasive test that 
can provide details of biventricular function and anatomy. 
Doppler ECHO can be used to calculate the right ventricle 
systolic pressure (RVSP) if tricuspid regurgitation jet is noted. 
Presence of tricuspid jet is crucial to this measurement. 
Pulmonary artery pressure approximately equals to right 
ventricular systolic pressure in the absence of pulmonary 
artery outflow obstruction or stenosis. The right ventricular 
pressure (RVP) is approximated by the modified Bernoulli 
equation as 4v2, in which v is the velocity of the tricuspid jet 
in meters per second. RVSP obtained by adding right atrial 
pressure (RAP) to the RVP.32 RAP estimate is based on either 
the height of jugular venous pulse or echocardiographic 
features of inferior vena cava:
  RVSP = 4v2 + RAP. 
In one study, RVSP could not be estimated in 34% 
of COPD patients.41 This was due to poor quality signal, 
inadequate tricuspid regurgitation (TR) or absence of 
Doppler-detected TR. Increased intrathoracic gas, expansion 
of the thoracic cage, and alterations in the position of the 
heart can adversely affect detection and measurement of   International Journal of COPD 2009:4 357
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TR jet velocity. In a large series of 374 patients with advanced 
lung disease (COPD 68%), significant correlation was seen 
between PAP estimated by Doppler ECHO and RHC.42 
However, the study revealed several limitations of the ECHO 
in this population. Estimation of PAP was possible in 44% of 
patients with advanced lung disease similar to the previous 
study.41 Doppler ECHO-estimated systolic PAP was accurate 
(within 10 mm Hg of RHC measurement) in only 48% of 
patients. However, the accuracy of Doppler ECHO was higher 
in patients with obstructive lung disease than in ILD or pul-
monary vascular disease. The likelihood of estimating systolic 
PAP was lower in patients with marked air trapping define 
as residual volume 150% (40% versus 56%; P = 0.007).42 
In a study by Himelman and colleagues, the detection rate of 
TR jet could be improved from 56% to 92% (P  0.001) by 
the use of agitated saline contrast.43 These studies show low 
sensitivity of ECHO in estimating PAP in COPD patients and 
agitated saline contrast may improve the detection rate. Fisher 
and colleagues compared echocardiographic estimate of PAP 
with RHC. ECHO was performed within one hour post-RHC 
and was inaccurate (10 mm Hg variability) in 48% of cases. 
Overestimation and underestimation were noted with similar 
frequency and the magnitude of underestimation was more. 
This study shows the inadequacy of ECHO in both identifying 
and quantifying PAP.44
ECHO can provide reliable data on abnormal anatomy 
of left heart and functional parameters which potentially 
can lead to elevated PAP.45 Intra cardiac shunts and valvular 
abnormalities can be recognized. ECHO derived data on 
pericardial effusion, right atrial enlargement and degree of 
septal displacement in diastole can predict mortality in PH.46 
These markers indicated right ventricular failure in PAH 
patients. The applicability of these markers in COPD-related 
PH is unknown.
Chest computed tomography
Computerized tomography (CT) of the chest is an emerging 
diagnostic modality in PH evaluation. An advance in CT tech-
nology has led to improved imaging of heart and pulmonary 
vasculature. Contiguous 10 mm CT sections obtained with a 
15 second breath-holding spiral technique were obtained in 
normal and proven PH patients (mean PAP  20 mm Hg). 
Main PA diameter of 3.32 cm had 58% sensitivity and 95% 
specificity for presence of PAH.47 The mean PAP used in this 
study was lower than the accepted definition of PH. Multi-
detector row CT with three-dimensional volume rendering 
can elucidate pulmonary vein anatomy in the thorax.48 This 
technology defines the anatomic details of main pulmonary 
veins draining into the left atrium. Abnormalities in the 
pulmonary venous drainage can prompt evaluation for 
structural anomalies causing PH.49 Contracter and colleagues 
evaluated the role of helical CT chest in diagnosing right 
ventricular dysfunction after acute pulmonary embolism (PE). 
Right ventricular dilation and deviation of interventricular 
septum towards left ventricle were the criteria used to define 
right ventricle dysfunction. The sensitivity of CT chest for 
detecting right ventricle dysfunction was 78% and specificity 
100%, with a positive predictive value of 100%.50 Although, 
this was a retrospective study of 25 patients, chest CT may 
provide an option for evaluating right ventricle dysfunction 
in COPD patients especially when ECHO Doppler proves 
inadequate.
Magnetic resonance imaging
Cardiac magnetic resonance imaging (MRI) can provide 
anatomical details of the right ventricle and pulmonary 
vasculature. It can calculate multiple right ventricular 
parameters like right ventricular end systolic volume, 
right ventricular end diastolic volume, right ventricular 
stroke volume, and right ventricular ejection fraction. Right 
ventricular diastolic dysfunction appears to be prevalent in 
PH patients. Isovolumic relaxation time, normalized right 
ventricular early peak filling rate (E), atrium-induced peak 
filling rate (A), and E/A ratio can be obtained to evaluate 
right ventricular diastolic dysfunction.51 Gan and colleagues 
showed that increased isovolumetric relaxation time and 
decreased E/A ratio were indicative of right ventricular 
diastolic dysfunction.52 MRA with gadolinium was shown 
to be 77% sensitive and 98% specific in detection of PE in a 
prospective study of 141 patients with suspected PE.53
COPD-related PH is generally mild/moderate and may 
not be associated with right ventricle (right ventricular) 
dysfunction until later in the disease course. right ventricule 
is chronically pressure overloaded in PH leading to (initial) 
hypertrophy as opposed to acutely overloaded in acute 
embolism which leads to dilation and bowing of the septum. 
Therefore the CT technique may not be applicable as an early 
detection or screening tool. MRI might be a more sensitive 
technique for detection of PH associated markers like right 
ventricular diastolic dysfunction, increased right ventricular 
mass and PVR. Further research needs to be done to deter-
mine the utility of these techniques in COPD-related PH.
right heart catheterization
Right heart catheterization is the gold standard to diagnose PH. 
Heart catheterization provides accurate measurement of mean International Journal of COPD 2009:4 358
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pulmonary artery pressure to diagnose PH and pulmonary 
wedge pressure to determine the presence of pulmonary 
venous hypertension.32 Pulmonary vascular reactivity is 
assessed during the RHC and presence of reactivity has 
important therapeutic and prognostic implications in PAH.54 
The major drawback is the invasive nature of the procedure. 
No studies have evaluated its role in COPD. The clinical 
conundrum would be selection of patients. For obvious 
reasons all patients with COPD cannot be subjected to 
heart catheterization. The optimal strategy would be to 
perform it on patients exhibiting signs and symptoms of 
right heart dysfunction. The authors feel its major role is 
to find elevated wedge pressures. This would identify left 
ventricular dysfunction and appropriate measures can be 
undertaken. Management of isolated precapillary elevated 
pulmonary pressure in COPD is unknown currently. The 
treatment strategy and benefits of treatment are unanswered 
questions.
Serological markers
Elevated serum brain-type natriuretic peptide (BNP) is a 
marker of myocardial stretch. Elevation in plasma BNP 
with exercise in COPD patients with normal right ventricles 
at rest suggests exercise induced PH.55 Plasma BNP levels 
are higher in COPD patients compared to normal subjects. 
Elevated plasma BNP correlates with pulmonary artery 
systolic pressure.56 BNP cutoff value of 36 pg/ml has a 
sensitivity and specificity of 75% and 89% in diagnosing cor 
pulmonale in COPD.57 All the above studies are single center 
investigations with small number of patients. The caveat in 
these studies is the low BNP value and hence poor specificity 
due to potential overlap with normal subjects. Large studies 
need to be conducted to validate these findings. The use 
of BNP can identify patients with subclinical PH. Further 
research needed to understand the clinical implication of 
identifying pre-clinical PH in COPD.
Diagnostic strategy
COPD confounds the classical manifestations of PH. Usual 
signs and symptoms of PH may be absent. Signs of right heart 
failure should trigger an evaluation for PH (Figure 2). ECHO 
is the initial screening tool of choice for PH. This simple 
noninvasive test can provide estimate of right ventricular 
systolic and RAPs. The utility of diagnosing sub-clinical 
PH is currently unknown. The authors feel that identification 
of elevated PAP in COPD patients by an ECHO should be 
followed by a RHC for confirmation (Figure 2) and to exclude 
alternative etiologies as stated in Table 1.
Signs and symptoms suggestive 
of PH in COPD 
Echocardiogram: 
Estimate pulmonary 
artery pressures 
Elevated pulmonary artery pressure 
Right heart catheterization 
(to confirm diagnosis) 
Diagnostic studies to pursue 
alternate diagnosis (Table 1) 
Figure 2 Diagnostic approach to a COPD patient with suspected PH.
Abbreviations: COPD, chronic obstructive pulmonary disease; PH, pulmonary hypertension.International Journal of COPD 2009:4 359
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Therapeutics
Avoidance of airway irritants
Tobacco smoke is the most common cause of COPD. Multiple 
studies have reported improvement in functional markers, 
symptoms, morbidity and mortality in COPD with smoking 
cessation.58,59 Smoking cessation is an integral part of COPD 
management as stated by multiple health organizations. 
All smokers irrespective of symptoms should be coun-
seled on the deleterious effects of smoking and cessation 
strategies. Even though, no studies exist evaluating the effect 
of smoking cessation on PH, authors strongly recommend 
smoking cessation for COPD patients with PH due to the 
obvious clinical benefits. Recent epidemiological studies 
have shown the role of biofuel smoke in causation of COPD. 
An autopsy study has revealed pathological changes similar 
to tobacco induced lung disease.15 No evidence is available 
yet evaluating the role of avoidance in biofuel induced lung 
disease. If evidence from smoking studies is considered, then 
avoidance of biofuel smoke may have similar benefits.
Oxygen therapy
Oxygen therapy is a cornerstone of COPD management in 
patients with hypoxemia. Two seminal trails have shown the 
survival benefit with long-term oxygen therapy. The Nocturnal 
Oxygen Treatment Trial (NOTT) included subjects with 
arterial PaO2 55 mm Hg or less or arterial PaO2 59 mm Hg or 
less with coexisting peripheral edema, hematocrit at least 55% 
or P pulmonale on EKG. The trial demonstrated a survival 
benefit of continuous supplemental oxygen therapy over 
nocturnal oxygen use. The average duration of treatment was 
19.3 months. PVR and hematocrit reduced more in subjects 
that were on continuous oxygen therapy.60
The Medical Research Council (MRC) trial included 
patients with severe COPD, PaO2 between 40 and 60 mm Hg, 
hypercapnia and history of congestive heart failure.61 Subjects 
received either oxygen for at least 15 h/day, usually at 2 L 
per minute, or no oxygen. The follow-up period was five 
years. A survival benefit with the use of continuous oxygen 
over no oxygen noted after 500 days. In this study, subjects 
on room air showed increase in PAP while those on oxygen 
therapy showed no such increase. Both trials were not 
methodologically designed to determine the survival benefit 
of hemodynamic changes noted with oxygen therapy.
Hypoxemia plays a significant role in PH associated with 
COPD. Although inhaled NO and 100% oxygen decreased 
PAP in such patients, pulmonary gas exchange worsened 
due to ventilation-perfusion imbalance.62 Hemodynamic 
evaluation of COPD patients showed no correlation 
between right ventricular ejection fraction and PAP. A weak 
correlation between RVEF and PVR was noted providing 
a suggestion that as PVR increased the right ventricular 
function deteriorated.63 Low flow oxygen therapy improved 
RVEF during exercise in COPD patients when compared 
to room air.64 This study shows that oxygen therapy can 
improve right ventricular function during exercise. In 
another study, COPD patients received 28% oxygen for 
24 hours and mean PAP response was measured. Fall in mean 
PAP of  5 mm Hg was considered a significant response 
to oxygen and predicted improved survival.65
Oswald-Mammosser and colleagues evaluated the 
prognostic significance of PH in hypoxic COPD patients 
requiring supplemental oxygen.66 The five-year survival 
rate was of 62.2% in patients with PAP  25 mm Hg 
compared to 36.3% seen in subjects with PAP  25 mm Hg 
Table 2 Summary of few studies to treat COPD-related PH
Study Agent Result Comment
Nocturnal Oxygen Treatment 
Trial (NOTT)60
Oxygen Decrease in Pvr with continuous 
oxygen supplementation
Survival benefit with continuous oxygen use 
with reduction in Pvr and hematocrit
Medical research Council 
(MrC) trial61
Oxygen PAP stable with O2 supplementation 
compared to increase noted with 
room air
Survival benefit after 500 days of oxygen use
Zielinski J et al67 Oxygen Initial fall and subsequent stabilization 
of PAP with long term oxygen therapy
worsening airway disease in presence 
of long term oxygen therapy
vonbank et al69 Inhaled NO + oxygen Improved PAP and Pvr after 
three months of pulsed NO inhalation
Short study duration. Needs validation 
in long term studies
Alp et al75 Sildenafil Improvement in PAP,  Pvr and 6MwT 
acutely and after three months
Small subject population with six initially and 
five after three months follow-up
valerio G et al78  Bosentan  Improvement in PAP,  Pvr, and 6MwD  
after 18 months
Small subject population of 16 patients International Journal of COPD 2009:4 360
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(P  0.001). PaO2 levels were not significantly different in 
the two groups. In a study by Zielinski and colleagues, long 
term oxygen therapy minimally improved mean PAP in the 
first two years, however mean PAP returned to baseline and 
remained unchanged despite worsening hypoxemia in this 
cohort of hypoxemic COPD patients.67 These studies provide 
support for using oxygen in hypoxemic COPD patients that 
may confer a survival benefit to these patients.
vasodilator therapy
Multiple pharmacological agents have pulmonary vasodilatory 
effects. Studies in PAH have shown the effectiveness of these 
agents on pulmonary hemodynamics, however their utility 
in COPD-related PH remains to be determined.
Nitric oxide
Nitric oxide is an important endothelial derived pulmonary 
vasodilator that plays an important role in hypoxia-induced 
pulmonary vasoconstriction. Biochemically, it induces 
vasodilatation by increasing cyclic guanosine monophosphate 
(cGMP) levels in vascular smooth muscles.30 Administration 
of inhaled NO in COPD can lead to worsening of gas 
exchange due to impaired ventilation-perfusion matching.62 
NO with oxygen therapy can lead to pulmonary vasodilatation 
without the deleterious effect on gas exchange.
NO administered by inhalation through a nasal canula 
at a dose of 25 parts per million for 24 hours with oxygen, 
reduced PVR without significant change in mean PAP.68 
Breathing NO for 24 hours resulted in a significant increase 
in cardiac output. All subjects were on home oxygen and 
the mean PAP prior to intervention was 26.1 and remained 
unchanged post intervention A randomized prospective 
trial was conducted in hypoxic COPD patients with PH 
(mean PAP  25 mm Hg) with pulsed inhaled NO plus 
oxygen over three months.69 NO plus oxygen decreased 
PVR, mean PAP, and increased cardiac output without 
worsening oxygenation. This study shows the improvement 
in pulmonary hemodynamics with inhaled NO. Baigori 
and colleagues.explored the role of inhaled NO on pulmo-
nary hemodynamics in acute COPD exacerbation. Twelve 
mechanically ventilated patients with acute COPD exacer-
bation were administered inhaled NO (20 parts per million 
(ppm) for 20 minutes.70 Mean PAP fell, but arterial oxygen-
ation, RVEF, and cardiac output remained unchanged. Based 
on the current available studies we know that inhaled NO 
does lead to pulmonary hemodynamic benefits in COPD. 
However, the translation of this hemodynamic improvement 
into clinical benefit is unexplored in COPD-related PH 
population. The major limitation of this drug is the difficulty 
in delivery, maintaining dosage, and patient discomfort due 
to mode of delivery.
Prostacyclin
Prostacyclin is an endogenously produced pulmonary 
vasodilator. In a study by Archer and colleagues, prostacy-
clin infusion for 48 hours in mechanically ventilated COPD 
patients with PH and acute respiratory failure showed no 
significant benefit.71 PVR and SVR fell initially but response 
was unsustained despite optimization of prostacyclin dosage. 
PaO2 dropped in patients receiving prostacyclin infusion 
compared to placebo group despite comparable inspired 
oxygen concentration. Lack of efficacy of prostacyclin can 
be attributable to multiple reasons. One could be ventilation-
perfusion mismatch and worsening oxygenation in patients 
with parenchymal lung disease. Prostacyclin can increase 
intrapulmonary shunting causing lower systemic oxygen 
saturation. However, increased right ventricular output by 
prostacyclin may counterbalance the increased shunting. 
Further studies are required to address the balance of these 
counter effects of prostacyclin.
A newer compound, cicletanine enhances endogenous 
prostacylin production. Saadjain and colleagues administered 
cicletanine (50 mg daily) for 12 months to COPD patients 
with PH.72 In this small study, cicletanine resulted in a reduc-
tion of mean PAP and PVR after three and 12 months of 
treatment. There was a small but a nonsignificant reduction 
of PaO2. Further studies are needed to evaluate the role of 
this agent in PH due to COPD. Currently a large phase II 
clinical trial is under way evaluating the role of Cicletanine 
in PAH (see http://www.clinicaltrials.gov/). This study might 
provide further information about the effects on cicletanine 
on pulmonary vascular hemodynamics.
Phosphodiesterase inhibitors
Phosphodiesterase (PDE) inactivates cGMP, the second 
messenger of the prostacyclin pathway. The majority of 
PDE present in the lungs is PDE5. PDE5-inhibition blocks 
the degradation of cGMP and enhances the vasodilatory 
action of cGMP.
Sildenafil is the prototype drug in this category. In a 
heterogeneous group of secondary PH patients (patients 
with chronic thromboembolic disease, PH due to valvular 
abnormalities and COPD), response to sildenafil was 
studied. Sildenafil administration resulted in improved 
six-minute walk distance over long-term follow-up (range 
12–51 months).73 Changes in PVR were variable and ECHO International Journal of COPD 2009:4 361
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showed improvement in right ventricular function. In patients 
with PH and severe COPD and idiopathic pulmonary fibrosis, 
50 mg sildenafil three times daily resulted in subjective 
improvement in all subjects.74 In a study evaluating the 
role of sildenafil in six patients, the PVR index dropped. 
Cardiac output and cardiac index showed no significant 
improvement.75 One time 50 mg dose of intravenous silde-
nafil reduced PAP and PVR and after three months of oral 
therapy, six-minute walk significantly improved.76 Sildenafil 
decreased the rise in mean PAP with exercise irrespective of 
baseline PAP in patients with COPD. Few available studies 
have shown that sildenafil improves hemodynamics and 
functional markers in this patient population. Confirmation 
of these results in larger studies in COPD-related PH is 
pending.
endothelin receptor antagonist
Endothelin-1 is a powerful vasoconstrictive agent produced 
by vascular endothelium and plays a major role in vascular 
homeostasis. Blockage of endothelin receptor leads to 
pulmonary vasodilation. Studies have shown its efficacy 
in PAH. Administration of endothelin receptor antagonists 
such as Bosentan in PH secondary to COPD has yielded 
conflicting results. Bosentan administration in COPD-related 
PH patients for 12 weeks, resulted in worsening hypoxemia 
with no improvement in six-minute walk distance.77 Another 
study by Valerio and colleagues showed that Bosentan 
administration for 18 months resulted in an improvement in 
six-minute walk distance, PAP, and PVR.78 These conflicting 
results need to be reconciled in a large randomized clinical 
trial that is currently underway. However, given the lack of 
convincing evidence, the use of Bosentan in COPD-related 
PH is not recommended.
Conclusion
COPD-related PH is usually mild. Small subset of patients 
demonstrates significant PH and the clinical significance 
is limited to poor prognosis. Initial goal of management is 
to identify alternate remediable causes. There is no current 
therapy targeting PH in COPD. Smoking cessation and 
oxygen therapy remain the only proven therapies for COPD 
and should be recommended to all COPD patients. Anecdotal 
reports suggest utility of PDE5-inhibitor and prostacyclin in 
treatment of PH associated with COPD. Targeted agents and 
strategies are still to be discovered.
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